Policy & Regulation
Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland
12 January 2021 - - Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the COVID-19 Moderna Vaccine in Switzerland, US-based biotechnology company Moderna, Inc. (NASDAQ: MRNA) said.

The authorization is given according to the ordinary approvals procedure and is based on a rolling submission of data and the totality of scientific evidence shared by the company, including a data analysis from the pivotal Phase 3 clinical study announced on November 30.

The Swiss Federal government has secured 7.5m doses of the COVID-19 Vaccine Moderna. Following TODAY's authorization, the first deliveries are expected to begin in Switzerland in the next week.

Moderna has also received authorization for its COVID-19 vaccine from regulatory authorities in the United States, Canada, Israel, the European Union and the United Kingdom.

Additional authorizations are currently under review in other countries and by the World Health Organization.